1. Home
  2. AGBK vs ANL Comparison

AGBK vs ANL Comparison

Compare AGBK & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AGI Inc Class A Common Shares

AGBK

AGI Inc Class A Common Shares

N/A

Current Price

$5.88

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$15.69

Market Cap

998.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AGBK
ANL
Founded
1999
2004
Country
Brazil
United States
Employees
N/A
N/A
Industry
Commercial Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
998.8M
IPO Year
2025
2022

Fundamental Metrics

Financial Performance
Metric
AGBK
ANL
Price
$5.88
$15.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
1
Target Price
$17.20
★ $20.00
AVG Volume (30 Days)
155.2K
★ 156.7K
Earning Date
05-05-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$36.02
Revenue Next Year
$235.22
N/A
P/E Ratio
$46.19
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.73
$0.88
52 Week High
$12.21
$17.25

Technical Indicators

Market Signals
Indicator
AGBK
ANL
Relative Strength Index (RSI) 32.42 55.70
Support Level N/A $12.07
Resistance Level $7.42 $17.25
Average True Range (ATR) 0.21 1.11
MACD -0.07 -0.02
Stochastic Oscillator 10.14 45.26

Price Performance

Historical Comparison
AGBK
ANL

About AGBK AGI Inc Class A Common Shares

AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: